Fulgent Genetics, Inc. (FLGT)
| Market Cap | 2.76B |
| Revenue (ttm) | 773.39M |
| Net Income (ttm) | 416.96M |
| Shares Out | 28.83M |
| EPS (ttm) | 15.82 |
| PE Ratio | 5.81 |
| Forward PE | 7.41 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 29 |
| Last Price | $91.92 |
| Previous Close | $95.23 |
| Change ($) | -3.31 |
| Change (%) | -3.48% |
| Day's Open | 95.14 |
| Day's Range | 90.08 - 95.69 |
| Day's Volume | 613,322 |
| 52-Week Range | 25.03 - 189.89 |
It may be curtains for the apes' high-profile, most-shorted stocks, but others may become the real deal with other bullish investors. The post 3 Smaller Most-Shorted Stocks to Buy appeared first on Inve...
TEMPLE CITY, Calif.--(BUSINESS WIRE)---- $FLGT--In the headline and first paragraph, first sentence of release, the date should read: Monday, August 9, 2021 (instead of Thursday, August 5, 2021). The up...
TEMPLE CITY, Calif.--(BUSINESS WIRE)---- $FLGT--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its sc...
The stock has traded with the ebbs and flows of COVID cases, but its testing has consistently delivered for its impressive list of customers.
Few companies had bigger tailwinds from COVID-19. What comes next could be even more exciting.
Despite easing restrictions, COVID is going to be around a lot longer than many think.
A steep sell-off is required for these stocks to become bargain buys.
FULGENT GENETIC (FLGT) closed the most recent trading day at $85.94, moving -0.13% from the previous trading session.
FULGENT GENETIC (FLGT) closed at $87.17 in the latest trading session, marking a -0.31% move from the prior day.
All is not lost for this COVID-19 testing company.
FULGENT GENETIC (FLGT) closed at $83.53 in the latest trading session, marking a +1.17% move from the prior day.
Ongoing COVID-19 testing and deals in the core business could keep growth high for longer than many think.
In the latest trading session, FULGENT GENETIC (FLGT) closed at $75.69, marking a +1.16% move from the previous day.
As we kicked off 2021, we highlighted two top contrarian picks for the new year.
These seven healthcare stocks are in a good position to take off as baby boomers continue to age into retirement. The post 7 Healthcare Stocks to Buy for Changing Demographics appeared first on Investor...
Wall Street is nervous, but these companies see growth beyond the pandemic.
Traders often look at short interest to get a sense of how many people are bearish on a stock and how strong the possibility of a short squeeze is. But simply looking at the size of the outstanding shor...
Genetic testing for the coronavirus is slowing.
Hint: It has something to do with COVID-19.
TEMPLE CITY, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “Company”), a technology company providing comprehensive testing solutions through its scalable tec...
More than 4,500% revenue growth gave Wall Street and shareholders something to cheer about.
FULGENT GENETIC (FLGT) delivered earnings and revenue surprises of 10.02% and 13.35%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
FULGENT GENETIC (FLGT) closed the most recent trading day at $73.01, moving +1.61% from the previous trading session.
TEMPLE CITY, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “company”), a technology company providing large-scale COVID-19 testing services and comprehensive testing s...
TEMPLE CITY, Calif.--(BUSINESS WIRE)---- $FLGT--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “Company”), a technology company providing comprehensive testing solutions through its sc...
Good news for the U.S. has been bad news for shareholders.
COVID-19 testing and NGS-based testing solutions are expected to have contributed to Fulgent Genetics' (FLGT) Q1 earnings.
FULGENT GENETIC (FLGT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FULGENT GENETIC (FLGT) closed at $87.64 in the latest trading session, marking a +0.52% move from the prior day.
The genetic testing giant's journey resembles the path of past winners.
The government is going to invest heavily in COVID-19 research and tracking, and these companies are likely to benefit.
FULGENT GENETIC (FLGT) closed at $86.78 in the latest trading session, marking a -0.99% move from the prior day.
If you are screening the market for high-return investments, you may want to consider the three non-cyclical stocks listed below, as their earnings yields (as calculated via Joel Greenblatt (Trades, Por...
Less COVID-19 testing means less revenue for some companies.
Be wary of companies posting abnormal growth rates.
He also gave clues that point to a few possible targets.
If you want to enhance your likelihood to beat the market, one method is to select stocks that rank highly according to the "Magic Formula" criteria.
Growth last year was awesome, but there is something to be even more excited about.
TEMPLE CITY, Calif., April 16, 2021 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions throug...
In the latest trading session, FULGENT GENETIC (FLGT) closed at $88.95, marking a +1.37% move from the previous day.
They've underperformed the S&P 500 in the past month, but these stocks show lots of potential over the long term.
Recent advances in computer technology have lit a fuse under the genomic sequencing industry. And here's what investors need to know now.
FULGENT GENETIC (FLGT) closed at $85.24 in the latest trading session, marking a -0.42% move from the prior day.
A rebounding economy is a good time to thaw out your risk capital and start buying some high-risk stocks with long-term potential. The post 8 High-Risk Stocks to Buy That Are Worth Taking A Chance On ap...
Industry trends could support massive gains for shareholders over the next 10 years.
Shareholders could be big winners if the demand for COVID-19 testing lingers.
Investors seeking a multi-year growth opportunity should watch out for these three stocks.
About FLGT
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves insurance, hospitals, and medical institutions. It sells its tests through internal sales force, as well as through independent sales representatives in the United States ... [Read more...]
| Industry Diagnostics & Research | IPO Date Sep 29, 2016 |
| CEO Ming Hsieh | Employees 700 |
| Stock Exchange NASDAQ | Ticker Symbol FLGT |
Analyst Forecasts
According to 4 analysts, the average rating for FLGT stock is "Buy." The 12-month stock price forecast is 87.00, which is a decrease of -5.35% from the latest price.